National Comprehensive Cancer Network® (NCCN®) Preferred: Brigatinib is recommended as a preferred first-line treatment option (Category 1) for ALK+ metastatic NSCLC in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)2,a,b,c

SEE
ALK+ mNSCLC
THINK
BRAIN METASTASES CHOOSE ALUNBRIG® (brigatinib)

ALUNBRIG® (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

See Results From ALTA 1L
NOW APPROVED:
FoundationOne®CDx

Identify patients eligible
for ALUNBRIG1

ONCLive

Dr. Alex Spira, Director of the Virginia Cancer Specialists Research Institute, discusses ALUNBRIG for the treatment of adult patients with ALK+ mNSCLC.

Watch the Webcast

Stay Connected

Register to receive useful information and updates about ALUNBRIG.

Register Now!

FoundationOne®CDx is a qualitative, next-generation sequencing–based, in vitro, diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures, including microsatellite instability (MSI) and tumor mutational burden (TMB), and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com.



References

1. FoundationOne CDx summary of safety and efficacy, Foundation Medicine, Inc; 2021. Accessed July 1, 2021. www.F1CDxLabel.com. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer v.4.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed June 4, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue +

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue +

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel +

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.


 
 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More